Tazemetostat
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Conditions
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Trial Timeline
Apr 9, 2018 → Dec 17, 2021
NCT ID
NCT03456726About Tazemetostat
Tazemetostat is a phase 2 stage product being developed by Eisai for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03456726. Target conditions include Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05228158 | Pre-clinical | Active |
| NCT03456726 | Phase 2 | Completed |
| NCT03009344 | Phase 1 | Completed |
Competing Products
20 competing products in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma